Pfizer and BioNTech Report Results of BNT162b2 to Prevent COVID-19
Shots: The P-III study evaluating BNT162b2 (COVID-19 Vaccine) vs PBO in >44,000 participants age ≥16 yrs with 927 confirmed symptomatic cases of COVID-19 The results […]
Shots: The P-III study evaluating BNT162b2 (COVID-19 Vaccine) vs PBO in >44,000 participants age ≥16 yrs with 927 confirmed symptomatic cases of COVID-19 The results […]
Shots: The approval is based on P-ll/lll study involve the assessment of Comirnaty (BNT162b2) vs PBO in 44,000 patients aged ≥16 yrs. in the ratio […]
Shots: Pfizer & BioNTech received the US FDA’s EUA for BNT162b2 for patients aged ≥16yrs with COVID-19. The companies are gathering additional data & prepared […]
Shots: Health Canada has granted authorization under interim order for the emergency use of BNT162b2. The distribution of the vaccine in Canada will be prioritized […]
Shots: Pfizer & BioNTech reports that the MHRA in the UK has granted a temporary authorization for the EU for BNT162b2 against COVID-19. The distribution […]
Shots: The companies have submitted CMA to the EMA for BNT162b2, against COVID-19. The submission completes the rolling review process initiated on Oct 6, 2020 […]
Shots: The companies initiated the P-II study of their COVID-19 vaccine in China. The trial will generate data to support the BLA filing for approval […]
Shots: The primary efficacy analysis demonstrated that BNT162b2 is 95% effective against COVID-19 beginning 28 days after the first dose. The study evaluated 170 confirmed […]
Shots: The companies sign an agreement with the EC to supply 200M doses of BNT162b2 mRNA-based vaccine candidate against SARS-CoV-2 to EU member states, with […]
Shots: The Rolling Submission is based on the preliminary results from pre-clinical and early clinical studies in adults, which shows that BNT162b2 triggers the production […]
The companies also said their Phase II/III study, slated to enroll about 30,000 participants, had already dosed more than 11,000.
The companies said they had started a Phase II/III trial BNT162b2. The news comes the day after Moderna announced the launch of its Phase III […]
Copyright © 2024 | WordPress Theme by MH Themes